Amgen’s MARITIME-SWITCH Trial Targets GLP-1 Switchers in the Growing Obesity Drug Market
Amgen Inc (AMGN) announced an update on their ongoing clinical study.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Amgen’s new Phase 3 MARITIME-SWITCH trial looks at adults with obesity or overweight who move from older GLP-1 drugs to Amgen’s next‑gen shot, maridebart cafraglutide. The goal is to see if switching can keep or improve weight loss while staying safe and easy to tolerate, a key question as the market for obesity drugs expands fast.
The study tests maridebart cafraglutide, also called AMG 133, given as a shot under the skin. It is designed to build on current GLP-1 drugs by offering strong weight loss with a dosing schedule that could be more convenient and support long‑term use.
This is an interventional Phase 3 study where participants are randomly assigned to one of two maridebart cafraglutide dosing schedules. Both patients and study staff are blinded to dose schedule, and the main aim is treatment, with a focus on weight change, safety and how well people stay on therapy.
The trial was first submitted on May 4, 2026, marking the formal launch of recruitment. The record was last updated on June 10, 2026, signaling that the design and status are current even though primary and final completion dates have not yet been posted.
For investors, a successful switch study could strengthen Amgen’s position in obesity care and support upside for AMGN if efficacy and safety look competitive. The trial sits in a field led by Novo Nordisk and Eli Lilly, so any sign that Amgen’s asset can win share from existing GLP‑1 drugs will be watched closely by the market.
The MARITIME-SWITCH study is currently recruiting and recently updated, with more details and ongoing status available on the ClinicalTrials portal.
To learn more about AMGN’s potential, visit the Amgen Inc drug pipeline page.
